Blog
RSS FeedPosted by Michael Wonder on 08 Apr 2016
Additional benefit of crizotinib for the first-line treatment of bronchial carcinoma is not proven
1 April 2016 - Crizotinib (Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) ...
Posted by Michael Wonder on 08 Apr 2016
New Zealand’s medicines landscape
8 April 2016 - Medicines New Zealand believes New Zealanders deserve better access to medicines when they need them. ...
Posted by Michael Wonder on 07 Apr 2016
PBAC Guidelines review update
7 April 2016 - The public consultation process on the draft revised PBAC Guidelines (Version 5.0) is now closed. ...
Posted by Michael Wonder on 06 Apr 2016
Genvoya in HIV: positive effects predominate in some adults, negative effects in others says Germany's IQWiG
1 April 2016 - The fixed-dose combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide has been available under the ...
Posted by Michael Wonder on 04 Apr 2016
CADTH calls for patient input on submissions from Boehringer Ingelheim & Servier
4 April 2016 - CADTH has received notice of pending submissions from Boehringer Ingelheim for empagliflozin with metformin hydrochloride (Synjardy) for ...
Posted by Michael Wonder on 04 Apr 2016
Roche seeks to avoid cancer drug drama with U.K. price talks
1 April 2016 - Roche Holding AG said it’s open to discussing ways to set prices for tumor-fighting treatments in the ...
Posted by Michael Wonder on 04 Apr 2016
Efmoroctocog alfa for haemophilia A: IQWIG says an additional benefit is not proven
1 April 2016 - Efmoroctocog alfa (trade name: Elocta) has been approved since November 2015 for people with type A haemophilia. ...
Posted by Michael Wonder on 04 Apr 2016
Medicines sector reforms deliver consumer benefits and a sustainable PBS
4 April 2016 - Consumers, taxpayers and the national health system will benefit from the significant savings being delivered by medicine ...
Posted by Michael Wonder on 04 Apr 2016
Patients could suffer as drug costs threaten to bankrupt NHS
2 April 2016 - Patients may miss out on vital drugs as doctors warned that high costs could cause the health ...
Posted by Michael Wonder on 04 Apr 2016
'Hundreds of cancer drugs' to enter market in next five years: report
4 April 2016 - Businessman Ron Walker considers himself among the luckiest cancer survivors. ...
Posted by Michael Wonder on 03 Apr 2016
Affordable access to innovative cancer medicines — don’t forget the prices
4 April 2016 - On 17 September 2015, the much anticipated Senate report on the Availability of new, innovative and specialist ...
Posted by Michael Wonder on 02 Apr 2016
HIV-positive children and adolescents: additional benefit of rilpivirine not proven
1 April 2016 - Under the trade name Edurant, rilpivirine hydrochloride as single agent has been approved already since 2011 for ...
Posted by Michael Wonder on 01 Apr 2016
NHS England funds Janssen's HIV pill Rezolsta
1 April 2016 - NHS England will release crucial funding for HIV therapy Rezolsta, its once-daily, fixed-dose combination of darunavir ethanolate ...
Posted by Michael Wonder on 31 Mar 2016
NICE tackles complex health issues for people with multimorbidity
31 March 2016 - NICE has issued draft guidance to help optimise care for people with 2 or more long-term health ...
Posted by Michael Wonder on 31 Mar 2016
Schedule of Pharmaceutical Benefits - 1 April 2016 update
1 April 2016 - The April 2016 issue of the Schedule sees a number of new/revised listings such as arsenic trioxide ...